Nanoparticles for targeted delivery of topical therapies to the respiratory tract


This technology uses nanoparticles for targeted delivery of therapeutic agents to the respiratory tract for local or systemic therapies. This novel nanoparticle-based drug delivery invention overcomes common problems associated with other respiratory drug delivery mechanisms by enabling the active therapeutic agents to remain in place for hours without being swallowed and without impairing respiratory cilia.  Other respiratory delivery vehicles, such as gels, ointments, etc. are too viscous and impair mucociliary clearance, leading to stasis of secretions and infections.

The system is highly adaptable as it is possible to precisely engineer the desired effect of the nanoparticle and employ a variety of therapeutic agents. Tunable features include cell target, binding capacity, length of time nanoparticle is bound, type and amount of therapeutic agent delivered, and rate of delivery.  Additionally, a wide variety of therapeutic agents may be applied.


· Conditions of the respiratory tract, such as sinusitis, allergic rhinitis, asthma, pneumonia, bronchitis, sinus or lung neoplasms, etc.

· Treatment of systemic disorders in which transmucosal routes of administration are preferred, i.e. diabetes (intranasal insulin), hormonal disorders (dDAVP), and migraine (intranasal imitrex

· COPD therapy

· Treatment to prevent or mitigate effects related to exposure to tobacco smoke, diesel exhaust, etc.)


· Active ongoing funded research with bioengineering and clinical collaboration

· Ability to make approved drugs more effective

· Flexible system with tunable characteristics (desired target, drug release profile)

· Extended drug delivery compared to alternative methods without impairing respiratory cilia  

· Can add multiple targeted cells or multiple active molecules


Related Publications:

·  Mulligan, RM; Atkinson, C; Vertegel, AA; Reukov, V; Schosser, RJ; Cigarette smoke extract stimulates interleukin-8 production in human airway epithelium and is attenuated by superoxide dismutase in vitro. Am J Rhinol Allergy. 2009 Nov-Dec;23(6):e1-4.


Inventors:                        Alexey Vertegel, Rodney Schloesser

Protection Status:           Patent application filed

Licensing Status:            Available for licensing

Additional Terms:          Biodegradable, Nanoparticles, Microspheres, Microbeads, Nasal Delivery, Respiratory, Corticosteroids

CURF Ref No:                09-002



Patent Information:
Biomedical Sciences
For Information, Contact:
Lisa Perpall
Commercialization Officer
Clemson University Research Foundation
Alexey Vertegel
Rodney Schloesser
Medical Device
Nanoscale Drug Delivery
Molecular Therapies
© 2014. All Rights Reserved. Powered by Inteum